<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049035</url>
  </required_header>
  <id_info>
    <org_study_id>MET39</org_study_id>
    <secondary_id>UTN: U1111-1112-2593</secondary_id>
    <nct_id>NCT01049035</nct_id>
  </id_info>
  <brief_title>A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine (TetraMen-T) in Infants and Toddlers</brief_title>
  <official_title>Safety and Immunogenicity of a Quadrivalent Meningococcal (A, C, Y and W-135) Tetanus Protein Conjugate Vaccine (TetraMen-T) Administered in Infants and Toddlers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the optimal vaccination schedule for a Quadrivalent
      Meningococcal (A, C, Y and W-135) Tetanus Protein Conjugate Vaccine (TetraMen-T) in order to
      provide an effective protein conjugate quadrivalent meningococcal vaccine in the population
      with the highest incidence of disease.

      Objectives:

        -  To describe the safety profile of TetraMen-T vaccine administered at 5 different
           schedules and concomitantly with routine pediatric vaccinations.

        -  To describe the immunogenicity profile of TetraMen-T vaccine administered at 5 different
           schedules and concomitantly with routine pediatric vaccinations.

        -  To describe the immunogenicity profiles of selected licensed pediatric vaccines
           (Pentacel, Prevnar, M-M-RII and Varivax) when administered either concomitantly with or
           without TetraMen-T vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will receive study vaccinations beginning at age 2, 6, or 12 months, depending
      on the assigned schedule in their randomized groups. All participants will undergo safety and
      immunogenicity assessments according to the schedule for their assigned group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To provide information concerning the immunogenicity of meningococcal tetanus protein conjugate (TetraMen-T) vaccine.</measure>
    <time_frame>30 days post 4- or 6-month vaccination; before and 30 days post-final vaccinations.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To provide information concerning the safety after administration of meningococcal tetanus protein conjugate (TetraMen-T) vaccine.</measure>
    <time_frame>0-7 days post-vaccination and entire study duration</time_frame>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">580</enrollment>
  <condition>Meningitis</condition>
  <condition>Meningococcal Infection</condition>
  <arm_group>
    <arm_group_label>TetraMen-T Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive TetraMen-T vaccine at 2, 4, 6, and 12 Months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TetraMen-T Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive TetraMen-T vaccine at 2, 4, 6, and 15 Months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TetraMen-T Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive TetraMen-T vaccine at 2, 4, and 12 Months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TetraMen-T Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive TetraMen-T vaccine at 6 and 12 Months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TetraMen-T Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive TetraMen-T vaccine at 12 Months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 6</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will not receive TetraMen-T vaccine; Only routine vaccines at 2, 4, 6, and 12 Months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 7</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will not receive TetraMen-T vaccine; Only routine Vaccines at 2, 4, 6, and 15 Months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Polysaccharide Tetanus Protein Conjugate</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>TetraMen-T Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Polysaccharide Tetanus Protein Conjugate</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>TetraMen-T Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Polysaccharide Tetanus Protein Conjugate</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>TetraMen-T Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Polysaccharide Tetanus Protein Conjugate</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>TetraMen-T Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Polysaccharide Tetanus Protein Conjugate</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>TetraMen-T Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pentacel®</intervention_name>
    <description>As in the prescribing information (All are licensed vaccines)</description>
    <arm_group_label>Study Group 6</arm_group_label>
    <arm_group_label>Study Group 7</arm_group_label>
    <other_name>Routine pediatric vaccines</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>M-M-R®II</intervention_name>
    <description>As in the prescribing information</description>
    <arm_group_label>Study Group 6</arm_group_label>
    <arm_group_label>Study Group 7</arm_group_label>
    <other_name>Routine licensed pediatric vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Varivax®</intervention_name>
    <description>As in the prescribing information</description>
    <arm_group_label>Study Group 6</arm_group_label>
    <arm_group_label>Study Group 7</arm_group_label>
    <other_name>Routine licensed pediatric vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar®</intervention_name>
    <description>As in the prescribing information</description>
    <arm_group_label>Study Group 6</arm_group_label>
    <arm_group_label>Study Group 7</arm_group_label>
    <other_name>Routine licensed pediatric vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RotaTeq®</intervention_name>
    <description>As in the prescribing information</description>
    <arm_group_label>Study Group 6</arm_group_label>
    <arm_group_label>Study Group 7</arm_group_label>
    <other_name>Routine licensed pediatric vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix-B®</intervention_name>
    <description>As in the prescribing information</description>
    <arm_group_label>Study Group 6</arm_group_label>
    <arm_group_label>Study Group 7</arm_group_label>
    <other_name>Routine licensed pediatric vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Groups 1, 2, 3, 6, and 7: Aged 42 to 89 days on the day of inclusion; Group 4: Aged 6
             months (180 days ± 14 days) on the day of inclusion; Group 5: Aged 12 months (365 days
             + 14 days) on the day of inclusion

          -  Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg

          -  Informed consent form has been signed and dated by the parent or other legally
             acceptable representative

          -  Participant and parent/guardian are able to attend all scheduled visits and to comply
             with all trial procedures

          -  Group 4 only: Prior receipt of Pentacel and Prevnar at 2 and 4 months; 1 or 2 doses of
             rotavirus vaccine; and 2 or 3 previous doses of hepatitis B vaccine Group 5 only:
             Prior receipt of Pentacel and Prevnar at 2, 4, and 6 months; 2 or 3 doses of rotavirus
             vaccine; and 3 previous doses of hepatitis B vaccine

        Exclusion Criteria :

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or medical procedure in the 4 weeks preceding the first trial vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Receipt of any vaccine in the 4 weeks preceding the first trial vaccination

          -  Planned receipt of any vaccine in the 4 weeks following any trial vaccination, with
             the exception of influenza vaccine, which may be received 14 days before or after
             TetraMen-T vaccine

          -  Previous vaccination against meningococcal disease with either the trial vaccine or
             another vaccine

          -  Receipt of blood or blood-derived products in the past 30 days, which might interfere
             with assessment of the immune response

          -  Known or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy; or
             long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2
             consecutive weeks)

          -  Known personal or maternal seropositivity for human immunodeficiency virus (HIV),
             hepatitis B vaccine, or hepatitis C, as reported by the parent/guardian

          -  History of meningococcal infection, confirmed either clinically, serologically, or
             microbiologically

          -  At high risk for meningococcal infection during the trial

          -  Known systemic hypersensitivity to any of the vaccine components, or history of a
             life-threatening reaction to the vaccines used in the trial or to a vaccine containing
             any of the same substances

          -  Thrombocytopenia, as reported by the parent/guardian

          -  Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion,
             contraindicating intramuscular vaccination

          -  History of seizures

          -  Personal or family history of Guillain-Barré Syndrome (GBS)

          -  Chronic illness that, in the opinion of the investigator, is at a stage where it might
             interfere with trial conduct or completion

        Temporary contraindications to be resolved before vaccination:

          -  Febrile illness (temperature ≥38.0°C [≥100.4°F]) or moderate or severe acute
             illness/infection (according to investigator judgment) on the day of vaccination

          -  Group 5 only: Receipt of oral or injected antibiotic therapy within the 72 hours prior
             to the study blood draw. Topical antibiotics or antibiotic drops are not included in
             this exclusion criterion. (Note: This does not apply to the other groups at this time,
             as they will not be having a blood draw within 30 days of the initial visit.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>365 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clyde</city>
        <state>North Carolina</state>
        <zip>28721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barnwell</city>
        <state>South Carolina</state>
        <zip>29812</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <zip>37043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springville</city>
        <state>Utah</state>
        <zip>84663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofiaventis.com</url>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <disposition_first_submitted>April 16, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 16, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 25, 2013</disposition_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningitis</keyword>
  <keyword>Meningococcal Infection</keyword>
  <keyword>Neisseria meningitidis</keyword>
  <keyword>Tetravalent Meningococcal Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

